We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
C.R. Bard Shareholders Approve Merger With Becton, Dickinson
Read MoreHide Full Article
Murray Hill, NJ-based C. R. Bard, Inc. announced that the majority of its shareholders have approved its merger with Becton, Dickinson and Company (BDX - Free Report) . Holders of approximately 99% of C.R. Bard’s shares that participated in the vote favored the merger. Management expects to complete the merger in the fourth quarter of 2017.
The Deal
On Apr 23, Becton, Dickinson, a leading global medical technology company, announced that it will acquire C.R. Bard for $24 billion. The agreement is expected to close in the fourth quarter of 2017. We view the acquisition as a strategic fit which will generate benefits from complementary businesses and geographical expansion.
We believe that the development will provide benefits of medication management and infection prevention to C.R. Bard’s customers and bolster its foothold in the global medical devices market. In this regard, the company has registered more than 500 products internationally in full-year 2016.
Summing Up
The acquisition is expected to strengthen the combined entity’s footprint in the home healthcare market in the U.S. On this note, a research report by ‘Markets and Markets’ reveals that the home healthcare market is expected to reach a total of $349.8 billion by 2020, growing at a CAGR of 9.0%.
However, the combined entity is likely to face some challenges with regard to the integration of the new businesses and the costs associated with them. Apart from this, increased competition, delay in order renewal process and constricted federal spending are other concerns.
Key Picks
Currently, C.R. Bard carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical sector are Edwards Lifesciences Corporation (EW - Free Report) and Dextera Surgical Inc. .
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. Notably, the stock returned 5.9% over the last three months.
Dextera has a projected sales growth of 54.8% for the current year. The stock promises a long-term expected earnings growth rate of 25%.
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future. Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential.See these stocks now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
C.R. Bard Shareholders Approve Merger With Becton, Dickinson
Murray Hill, NJ-based C. R. Bard, Inc. announced that the majority of its shareholders have approved its merger with Becton, Dickinson and Company (BDX - Free Report) . Holders of approximately 99% of C.R. Bard’s shares that participated in the vote favored the merger. Management expects to complete the merger in the fourth quarter of 2017.
The Deal
On Apr 23, Becton, Dickinson, a leading global medical technology company, announced that it will acquire C.R. Bard for $24 billion. The agreement is expected to close in the fourth quarter of 2017. We view the acquisition as a strategic fit which will generate benefits from complementary businesses and geographical expansion.
We believe that the development will provide benefits of medication management and infection prevention to C.R. Bard’s customers and bolster its foothold in the global medical devices market. In this regard, the company has registered more than 500 products internationally in full-year 2016.
Summing Up
The acquisition is expected to strengthen the combined entity’s footprint in the home healthcare market in the U.S. On this note, a research report by ‘Markets and Markets’ reveals that the home healthcare market is expected to reach a total of $349.8 billion by 2020, growing at a CAGR of 9.0%.
However, the combined entity is likely to face some challenges with regard to the integration of the new businesses and the costs associated with them. Apart from this, increased competition, delay in order renewal process and constricted federal spending are other concerns.
Key Picks
Currently, C.R. Bard carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical sector are Edwards Lifesciences Corporation (EW - Free Report) and Dextera Surgical Inc. .
Notably, Edwards Lifesciences sports a Zacks Rank #1 (Strong Buy), while Dextera has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. Notably, the stock returned 5.9% over the last three months.
Dextera has a projected sales growth of 54.8% for the current year. The stock promises a long-term expected earnings growth rate of 25%.
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future. Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>